Top Ten Lessons Learned from Trials in Oligometastatic Cancers

Recent evidence supports the role of aggressive local treatment in the oligometastatic setting. In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic disease, outcomes, toxicity, costs, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Vivian S., Palma, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873316/
https://www.ncbi.nlm.nih.gov/pubmed/36567069
http://dx.doi.org/10.4143/crt.2022.1460
_version_ 1784877569161560064
author Tan, Vivian S.
Palma, David A.
author_facet Tan, Vivian S.
Palma, David A.
author_sort Tan, Vivian S.
collection PubMed
description Recent evidence supports the role of aggressive local treatment in the oligometastatic setting. In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic disease, outcomes, toxicity, costs, and the combination of ablative therapies with systemic therapy, including immunotherapy. Barriers to accrual for trials and upcoming phase III trials are also reviewed. These lessons may help to inform clinical practice and may be the basis for future research in the oligometastatic space.
format Online
Article
Text
id pubmed-9873316
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-98733162023-02-02 Top Ten Lessons Learned from Trials in Oligometastatic Cancers Tan, Vivian S. Palma, David A. Cancer Res Treat Special Article Recent evidence supports the role of aggressive local treatment in the oligometastatic setting. In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic disease, outcomes, toxicity, costs, and the combination of ablative therapies with systemic therapy, including immunotherapy. Barriers to accrual for trials and upcoming phase III trials are also reviewed. These lessons may help to inform clinical practice and may be the basis for future research in the oligometastatic space. Korean Cancer Association 2023-01 2022-12-16 /pmc/articles/PMC9873316/ /pubmed/36567069 http://dx.doi.org/10.4143/crt.2022.1460 Text en Copyright © 2023 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Article
Tan, Vivian S.
Palma, David A.
Top Ten Lessons Learned from Trials in Oligometastatic Cancers
title Top Ten Lessons Learned from Trials in Oligometastatic Cancers
title_full Top Ten Lessons Learned from Trials in Oligometastatic Cancers
title_fullStr Top Ten Lessons Learned from Trials in Oligometastatic Cancers
title_full_unstemmed Top Ten Lessons Learned from Trials in Oligometastatic Cancers
title_short Top Ten Lessons Learned from Trials in Oligometastatic Cancers
title_sort top ten lessons learned from trials in oligometastatic cancers
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873316/
https://www.ncbi.nlm.nih.gov/pubmed/36567069
http://dx.doi.org/10.4143/crt.2022.1460
work_keys_str_mv AT tanvivians toptenlessonslearnedfromtrialsinoligometastaticcancers
AT palmadavida toptenlessonslearnedfromtrialsinoligometastaticcancers

Ejemplares similares